Spebrutinib (CC-292) Affects Markers of B Cell Activation, Chemotaxis, and Osteoclasts in Patients with Rheumatoid Arthritis: Results from a Mechanistic Study
Rheumatology and Therapy（2019）
Key words
Background methotrexate therapy,Bruton’s tyrosine kinase inhibitor,CC-292,Rheumatoid arthritis,Spebrutinib
AI Read Science
Must-Reading Tree
Example
Generate MRT to find the research sequence of this paper
Chat Paper
Summary is being generated by the instructions you defined